FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955755158> ?p ?o ?g. }

• W2955755158 abstract "A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events. Traditional rule-based designs require temporarily stopping recruitment whilst waiting to see whether enrolled patients develop toxicity. This can be both inefficient and introduces logistic challenges to recruitment in the clinic. We describe a novel two-stage dose assignment procedure designed for a phase I clinical trial (STARPAC), where a good estimation of prior was possible.The STARPAC design uses rule-based design until the first patient has a dose limiting toxicity (DLT) and then switches to a modified CRM, with rules to handle patient recruitment during follow-up of earlier patients. STARPAC design is compared via simulations with the TITE-CRM and 3 + 3 methods in various toxicity estimate (T1-5), rate of recruitment (R1-2), and DLT events timing (DT1-4), scenarios using several metrics: accuracy of maximum tolerated dose (MTD), numbers of DLTs, number of patients enrolled and those missed; duration of trial; and proportion of patients treated at the therapeutic dose or MTD.The simulations suggest that STARPAC design performed well in MTD estimation and in treating patients at the highest possible therapeutic levels. STARPAC and TITE-CRM were comparable in the number of patients required and DLTs incurred. The 3 + 3 design often had fewer patients and DLTs although this is due to its low escalation rate leading to poor MTD estimation. For the numbers of declined patients and MTD estimation 3 + 3 is uniformly worse, with STARPAC being better in those metrics for high toxicity scenarios and TITE-CRM better with low toxicity. In situations including doses with toxicities both above and below 30%, the STARPAC design outperformed TITE-CRM with respect to every metric.When considering doses with toxicities both above and below the target of 30% toxicities, the two-stage STARPAC dose escalation design provides a more efficient phase I trial design than either the traditional 3 + 3 or the TITE-CRM design. Trialists should model various designs via simulation to adopt the most efficient design for their clinical scenario.Clinical Trials NCT03307148 (11 October 2017)." @default.
• W2955755158 created "2019-07-12" @default.
• W2955755158 creator A5024033591 @default.
• W2955755158 creator A5025868896 @default.
• W2955755158 creator A5060584070 @default.
• W2955755158 date "2019-06-26" @default.
• W2955755158 modified "2023-09-25" @default.
• W2955755158 title "A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method" @default.
• W2955755158 cites W130028085 @default.
• W2955755158 cites W1552430425 @default.
• W2955755158 cites W1972747033 @default.
• W2955755158 cites W1973147485 @default.
• W2955755158 cites W2028274664 @default.
• W2955755158 cites W2030617093 @default.
• W2955755158 cites W2042990006 @default.
• W2955755158 cites W2045985885 @default.
• W2955755158 cites W2048488963 @default.
• W2955755158 cites W2050076340 @default.
• W2955755158 cites W2054383376 @default.
• W2955755158 cites W2062178754 @default.
• W2955755158 cites W2069446399 @default.
• W2955755158 cites W2069662864 @default.
• W2955755158 cites W2071462987 @default.
• W2955755158 cites W2091798603 @default.
• W2955755158 cites W2092844966 @default.
• W2955755158 cites W2093838072 @default.
• W2955755158 cites W2104438003 @default.
• W2955755158 cites W2139494088 @default.
• W2955755158 cites W2141086589 @default.
• W2955755158 cites W2150405633 @default.
• W2955755158 cites W2158740848 @default.
• W2955755158 cites W2162300921 @default.
• W2955755158 cites W2165480504 @default.
• W2955755158 cites W2167228337 @default.
• W2955755158 cites W2170202192 @default.
• W2955755158 cites W2171993420 @default.
• W2955755158 cites W2244282744 @default.
• W2955755158 cites W2312270541 @default.
• W2955755158 cites W2518057374 @default.
• W2955755158 cites W2935748138 @default.
• W2955755158 cites W3103950165 @default.
• W2955755158 doi "https://doi.org/10.1186/s12885-019-5801-3" @default.
• W2955755158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6595589" @default.
• W2955755158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31242873" @default.
• W2955755158 hasPublicationYear "2019" @default.
• W2955755158 type Work @default.
• W2955755158 sameAs 2955755158 @default.
• W2955755158 citedByCount "20" @default.
• W2955755158 countsByYear W29557551582020 @default.
• W2955755158 countsByYear W29557551582021 @default.
• W2955755158 countsByYear W29557551582022 @default.
• W2955755158 countsByYear W29557551582023 @default.
• W2955755158 crossrefType "journal-article" @default.
• W2955755158 hasAuthorship W2955755158A5024033591 @default.
• W2955755158 hasAuthorship W2955755158A5025868896 @default.
• W2955755158 hasAuthorship W2955755158A5060584070 @default.
• W2955755158 hasBestOaLocation W29557551581 @default.
• W2955755158 hasConcept C126322002 @default.
• W2955755158 hasConcept C127413603 @default.
• W2955755158 hasConcept C143998085 @default.
• W2955755158 hasConcept C162324750 @default.
• W2955755158 hasConcept C187736073 @default.
• W2955755158 hasConcept C188198153 @default.
• W2955755158 hasConcept C2777334693 @default.
• W2955755158 hasConcept C29730261 @default.
• W2955755158 hasConcept C535046627 @default.
• W2955755158 hasConcept C71924100 @default.
• W2955755158 hasConcept C78519656 @default.
• W2955755158 hasConcept C96250715 @default.
• W2955755158 hasConceptScore W2955755158C126322002 @default.
• W2955755158 hasConceptScore W2955755158C127413603 @default.
• W2955755158 hasConceptScore W2955755158C143998085 @default.
• W2955755158 hasConceptScore W2955755158C162324750 @default.
• W2955755158 hasConceptScore W2955755158C187736073 @default.
• W2955755158 hasConceptScore W2955755158C188198153 @default.
• W2955755158 hasConceptScore W2955755158C2777334693 @default.
• W2955755158 hasConceptScore W2955755158C29730261 @default.
• W2955755158 hasConceptScore W2955755158C535046627 @default.
• W2955755158 hasConceptScore W2955755158C71924100 @default.
• W2955755158 hasConceptScore W2955755158C78519656 @default.
• W2955755158 hasConceptScore W2955755158C96250715 @default.
• W2955755158 hasFunder F4320309086 @default.
• W2955755158 hasFunder F4320319985 @default.
• W2955755158 hasFunder F4320334626 @default.
• W2955755158 hasIssue "1" @default.
• W2955755158 hasLocation W29557551581 @default.
• W2955755158 hasLocation W29557551582 @default.
• W2955755158 hasLocation W29557551583 @default.
• W2955755158 hasLocation W29557551584 @default.
• W2955755158 hasLocation W29557551585 @default.
• W2955755158 hasLocation W29557551586 @default.
• W2955755158 hasOpenAccess W2955755158 @default.
• W2955755158 hasPrimaryLocation W29557551581 @default.
• W2955755158 hasRelatedWork W1856595486 @default.
• W2955755158 hasRelatedWork W1990807227 @default.
• W2955755158 hasRelatedWork W2016462949 @default.
• W2955755158 hasRelatedWork W2044343252 @default.
• W2955755158 hasRelatedWork W2150700051 @default.
• W2955755158 hasRelatedWork W2316124251 @default.
• W2955755158 hasRelatedWork W2383703011 @default.

• next